Department of Surgery, Dentistry, Pediatrics and Gynecology, Division of Cardiac Surgery, University of Verona, 37126 Verona, Italy.
Department of Cardiology, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.
Medicina (Kaunas). 2023 May 31;59(6):1060. doi: 10.3390/medicina59061060.
: To evaluate the early and long-term results of surgical treatment of isolated mitral native and prosthetic valve infective endocarditis. : All patients undergoing mitral valve repair or replacement for infective endocarditis at our institution between January 2001 and December 2021 were included in the study. The preoperative and postoperative characteristics and mortality of patients were retrospectively reviewed. A total of 130 patients, 85 males and 45 females, with a median age of 61 ± 14 years, underwent surgery for isolated mitral valve endocarditis during the study period. There were 111 (85%) native and 19 (15%) prosthetic valve endocarditis cases. Fifty-one (39%) patients died during the follow-up, and the overall mean patient survival time was 11.8 ± 0.9 years. The mean survival time was better in patients with mitral native valve endocarditis compared to patients with prosthetic valve endocarditis (12.3 ± 0.9 years vs. 8 ± 1.4 years; = 0.1), but the difference was not statistically significant. Patients who underwent mitral valve repair had a better survival rate compared to patients who had mitral valve replacement (14.8 ± 1.6 vs. 11.3 ± 1 years; = 0.06); however, the difference was not statistically significant. Patients who underwent mitral valve replacement with a mechanical prosthesis had a significantly better survival rate compared to patients who received a biological prosthesis (15.6 ± 1.6 vs. 8.2 ± 0.8 years; < 0.001). Patients aged ≤60 years had significantly better survival compared to patients aged >60 years (17.1 ± 1.1 vs. 8.2 ± 0.9; < 0.001). Multivariate analysis showed that the patient's age >60 years at the time of surgery was an independent risk factor for mortality, while mitral valve repair was a protective factor. Eight (7%) patients required reintervention. Freedom from reintervention was significantly higher in patients with mitral native valve endocarditis compared to patients with prosthetic valve endocarditis (19.3 ± 0.5 vs. 11.5 ± 1.7 years; = 0.04). : Surgery for mitral valve endocarditis is associated with considerable morbidity and mortality. The patient's age at the time of surgery represents an independent risk factor for mortality. Mitral valve repair should be the preferred choice whenever possible in suitable patients affected by infective endocarditis.
: 评估孤立性二尖瓣天然和人工瓣膜感染性心内膜炎的手术治疗的早期和长期结果。 : 本研究纳入了 2001 年 1 月至 2021 年 12 月期间我院因感染性心内膜炎接受二尖瓣瓣膜修复或置换手术的所有患者。回顾性分析患者术前和术后特征及死亡率。 在研究期间,共有 130 名患者(85 名男性和 45 名女性)接受了孤立性二尖瓣心内膜炎手术,中位年龄为 61 ± 14 岁。其中 111 例(85%)为原发性二尖瓣心内膜炎,19 例(15%)为人工瓣膜心内膜炎。51 例(39%)患者在随访期间死亡,总体平均患者生存时间为 11.8 ± 0.9 年。与人工瓣膜心内膜炎患者相比,原发性二尖瓣心内膜炎患者的平均生存时间更好(12.3 ± 0.9 年比 8 ± 1.4 年; = 0.1),但差异无统计学意义。与二尖瓣瓣膜置换术患者相比,二尖瓣瓣膜修复术患者的生存率更好(14.8 ± 1.6 比 11.3 ± 1 年; = 0.06);然而,差异无统计学意义。接受二尖瓣机械瓣膜置换术的患者的生存率明显优于接受生物瓣膜置换术的患者(15.6 ± 1.6 比 8.2 ± 0.8 年; < 0.001)。年龄≤60 岁的患者的生存率明显优于年龄>60 岁的患者(17.1 ± 1.1 比 8.2 ± 0.9 年; < 0.001)。多因素分析显示,手术时患者年龄>60 岁是死亡的独立危险因素,而二尖瓣瓣膜修复是保护因素。8 例(7%)患者需要再次介入治疗。与人工瓣膜心内膜炎患者相比,原发性二尖瓣心内膜炎患者的无再次介入治疗生存率明显更高(19.3 ± 0.5 比 11.5 ± 1.7 年; = 0.04)。 : 二尖瓣心内膜炎手术治疗相关发病率和死亡率较高。手术时患者年龄是死亡的独立危险因素。在适合感染性心内膜炎的患者中,二尖瓣瓣膜修复术应尽可能作为首选。